RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins
- 1 August 1988
- journal article
- research article
- Published by Elsevier in Journal of Steroid Biochemistry
- Vol. 31 (2) , 161-166
- https://doi.org/10.1016/0022-4731(88)90049-0
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Transformation of calf uterine progesterone receptor: analysis of the process when receptor is bound to progesterone and RU38486Biochemistry, 1987
- The Progesterone Antagonist RU 486New England Journal of Medicine, 1987
- Termination of Early Pregnancy by the Progesterone Antagonist RU 486 (Mifepristone)New England Journal of Medicine, 1986
- Progestin Effect on Cell Proliferation and 17β-Hydroxysteroid Dehydrogenase Activity in Normal Human Breast Cells in Culture*Journal of Clinical Endocrinology & Metabolism, 1986
- Antiprogestin-receptor complexes: Differences in the interaction of the antiprogestin RU38,486 and the progestin R5020 with the progesterone receptor of human breast cancer cellsBiochemical and Biophysical Research Communications, 1986
- The Antiprogestin RU38 486: Receptor-Mediated ProgestinVersusAntiprogestin Actions Screened in Estrogen-Insensitive T47DCOHuman Breast Cancer Cells*Endocrinology, 1985
- RU486, A Progestin and Glucocorticoid Antagonist, Inhibits the Growth of Breast Cancer Cells via the Progesterone Receptor*Journal of Clinical Endocrinology & Metabolism, 1985
- Mechanism of action of an antiprogesterone, RU486, in the rabbit endometriumEuropean Journal of Biochemistry, 1985
- Endometrial and Pituitary Responses to the Steroidal Antiprogestin RU 486in Postmenopausal WomenJournal of Clinical Endocrinology & Metabolism, 1985
- THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONSAnnals of the New York Academy of Sciences, 1949